Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Angela Hayes
Observed names:
A Hayes,
A. Hayes,
Hayes Angela,
Hayes, Angela
Institution:
Institute of Cancer Research
Observed institutions:
Institute of Cancer Research,
Genentech,
Cancer Research UK,
Institute of Cancer Research,
Vernalis (R&D) Limited (United Kingdom)
ORCID:
0000-0001-6788-5761
Observed ORCID:
0000-0001-6788-5761
OpenAlex ID:
A5061423488
The Identification of 2-(1 H -Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2- d ]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer
2008
·
Adrian J. Folkes
, Khatereh Ahmadi
, et al.
·
Journal of Medicinal Chemistry
·
814
NVP-AUY922: A Novel Heat Shock Protein 90 Inhibitor Active against Xenograft Tumor Growth, Angiogenesis, and Metastasis
2008
·
Suzanne A. Eccles
, Andy Massey
, et al.
·
Cancer Research
·
502
4,5-Diarylisoxazole Hsp90 Chaperone Inhibitors: Potential Therapeutic Agents for the Treatment of Cancer
2007
·
Paul A. Brough
, Wynne Aherne
, et al.
·
Journal of Medicinal Chemistry
·
475
Pharmacologic Characterization of a Potent Inhibitor of Class I Phosphatidylinositide 3-Kinases
2007
·
Florence I. Raynaud
, Suzanne Eccles
, et al.
·
Cancer Research
·
382
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941
2009
·
Florence I. Raynaud
, Suzanne A. Eccles
, et al.
·
Molecular Cancer Therapeutics
·
292
PDF
Combining Hit Identification Strategies: Fragment-Based and in Silico Approaches to Orally Active 2-Aminothieno[2,3-d]pyrimidine Inhibitors of the Hsp90 Molecular Chaperone
2009
·
Paul A. Brough
, Xavier Barril
, et al.
·
Journal of Medicinal Chemistry
·
188
Small Molecule Antagonists of the σ-1 Receptor Cause Selective Release of the Death Program in Tumor and Self-Reliant Cells and Inhibit Tumor Growth in Vitro and in Vivo
2004
·
Barbara A. Spruce
, Lorna A. Campbell
, et al.
·
Cancer Research
·
182
Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues
2007
·
Swee Y. Sharp
, Chrisostomos Prodromou
, et al.
·
Molecular Cancer Therapeutics
·
156
ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma
2019
·
Diana Carvalho
, Kathryn R. Taylor
, et al.
·
Communications Biology
·
133
PDF
Structure Enabled Design of BAZ2-ICR, A Chemical Probe Targeting the Bromodomains of BAZ2A and BAZ2B
2015
·
Ludovic Drouin
, Sally McGrath
, et al.
·
Journal of Medicinal Chemistry
·
117
PDF
In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors
2007
·
Swee Y. Sharp
, Kathy Boxall
, et al.
·
Cancer Research
·
117
Preclinical pharmacokinetics and metabolism of a novel prototype DNA-PK inhibitor NU7026
2005
·
B P Nutley
, N F Smith
, et al.
·
British Journal of Cancer
·
113
PDF
The Preclinical Pharmacology and Therapeutic Activity of the Novel CHK1 Inhibitor SAR-020106
2010
·
Michael I. Walton
, Paul D. Eve
, et al.
·
Molecular Cancer Therapeutics
·
110
CCT244747 Is a Novel Potent and Selective CHK1 Inhibitor with Oral Efficacy Alone and in Combination with Genotoxic Anticancer Drugs
2012
·
Mike I. Walton
, Paul D. Eve
, et al.
·
Clinical Cancer Research
·
103
Structure-Based Design of Orally Bioavailable 1H-Pyrrolo[3,2-c]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1)
2013
·
Sébastien Naud
, Isaac M. Westwood
, et al.
·
Journal of Medicinal Chemistry
·
88
Metabolism and pharmacokinetics of the cyclin-dependent kinase inhibitorR-roscovitine in the mouse
2005
·
Bernard P. Nutley
, Florence I. Raynaud
, et al.
·
Molecular Cancer Therapeutics
·
78
PDF
Achieving In Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders
2020
·
Benjamin R. Bellenie
, Kwai-Ming J. Cheung
, et al.
·
Journal of Medicinal Chemistry
·
75
The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eμ-MYC driven B-cell lymphoma
2015
·
Mike I. Walton
, Paul D. Eve
, et al.
·
Oncotarget
·
74
PDF
Discovery of a Chemical Probe Bisamide (CCT251236): An Orally Bioavailable Efficacious Pirin Ligand from a Heat Shock Transcription Factor 1 (HSF1) Phenotypic Screen
2016
·
Matthew D. Cheeseman
, Nicola E. A. Chessum
, et al.
·
Journal of Medicinal Chemistry
·
66
Structure-Guided Evolution of Potent and Selective CHK1 Inhibitors through Scaffold Morphing
2011
·
John C. Reader
, Thomas P. Matthews
, et al.
·
Journal of Medicinal Chemistry
·
64
PDF
Structure-Based Design of Potent and Selective 2-(Quinazolin-2-yl)phenol Inhibitors of Checkpoint Kinase 2
2010
·
John J. Caldwell
, Emma J. Welsh
, et al.
·
Journal of Medicinal Chemistry
·
51
High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers
2019
·
Simon J. Anderhub
, Grace Wing-Yan Mak
, et al.
·
Molecular Cancer Therapeutics
·
46
A systematic molecular and pharmacologic evaluation of AKT inhibitors reveals new insight into their biological activity
2020
·
Eleftherios Kostaras
, Teresa Kaserer
, et al.
·
British Journal of Cancer
·
43
PDF
Multiparameter Lead Optimization to Give an Oral Checkpoint Kinase 1 (CHK1) Inhibitor Clinical Candidate: ( R )-5-((4-((Morpholin-2-ylmethyl)amino)-5-(trifluoromethyl)pyridin-2-yl)amino)pyrazine-2-carbonitrile (CCT245737)
2016
·
James D. Osborne
, Thomas P. Matthews
, et al.
·
Journal of Medicinal Chemistry
·
42
PDF
Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases
2019
·
Chi Zhang
, Simon R. Stockwell
, et al.
·
Oncogene
·
40
PDF
Show more works
View as search
Works count:
153
Citation count:
4,931
H-index:
30
I10-index:
45
Year
Topic
Type